AN2 Therapeutics, Inc. (ANTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$53.5M
Cash & Equivalents
$12.1M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$162M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07301320 | Epetraborole in Patients With Mycobacterium Abscessus Lung Disease | PHASE2 | Recruiting | 84 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-04 | 8-K | AN2 Therapeutics, Inc. (ANTX) (CIK 0001880438) - EX-99.1 | EDGAR |